Shweta Paroha, Ravindra Dhar Dubey, Juhi Verma, Vikas Jain, Saleem Akbar, Ashwini Kumar Mishra, S L Neha, Laxmi Rani, Aman Kumar Mahto, Parvat Kumar Sahoo, Rikeshwer Prasad Dewangan
{"title":"Fabrication and Evaluation of Hyaluronic Acid Coated Albumin Nanoparticles for Delivery of Gemcitabine.","authors":"Shweta Paroha, Ravindra Dhar Dubey, Juhi Verma, Vikas Jain, Saleem Akbar, Ashwini Kumar Mishra, S L Neha, Laxmi Rani, Aman Kumar Mahto, Parvat Kumar Sahoo, Rikeshwer Prasad Dewangan","doi":"10.2174/0115672018317615240926163652","DOIUrl":null,"url":null,"abstract":"<p><p>Gemcitabine (Gem) is a well-known antineoplastic drug used for several solid tumors. The clinical application of gem is hampered owing to non-selectivity, short half-life, and drug resistance, which necessitate the development of a suitable novel formulation that can selectively target cancer sites. In the present work, Gem-loaded bovine serum albumin nanoparticles (Gem-BSANPs) have been prepared and coated with hyaluronic acid (HA-Gem-BSANPs). Particle size, zeta potential, TEM, and DSC analysis characterized the developed NPs. The mean particle size, PDI, and zeta potentials were observed to be 120.9 ± 5.87 vs 144.7 ± 5.67 and 28.66 ± 1.10 vs -45.72 ± 3.24, for Gem-BSANPs and HA-Gem-BSANPs, respectively. Interestingly, HA-coated Gem-BSANPs were found higher cytotoxic against A549 cell lines with better killing kinetics and mitochondrial membrane loss due to overexpression of CD44. The present work demonstrated that HA-Gem-BSANPs could be a potential strategy to improve the therapeutic efficacy of gem by selectively targeting to the tumor site.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115672018317615240926163652","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Gemcitabine (Gem) is a well-known antineoplastic drug used for several solid tumors. The clinical application of gem is hampered owing to non-selectivity, short half-life, and drug resistance, which necessitate the development of a suitable novel formulation that can selectively target cancer sites. In the present work, Gem-loaded bovine serum albumin nanoparticles (Gem-BSANPs) have been prepared and coated with hyaluronic acid (HA-Gem-BSANPs). Particle size, zeta potential, TEM, and DSC analysis characterized the developed NPs. The mean particle size, PDI, and zeta potentials were observed to be 120.9 ± 5.87 vs 144.7 ± 5.67 and 28.66 ± 1.10 vs -45.72 ± 3.24, for Gem-BSANPs and HA-Gem-BSANPs, respectively. Interestingly, HA-coated Gem-BSANPs were found higher cytotoxic against A549 cell lines with better killing kinetics and mitochondrial membrane loss due to overexpression of CD44. The present work demonstrated that HA-Gem-BSANPs could be a potential strategy to improve the therapeutic efficacy of gem by selectively targeting to the tumor site.